6/1/2022 | CVLM | Neurocrine Biosciences buys back more 2.25% convertibles due 2024
|
5/25/2022 | CVLM | Neurocrine Biosciences buys back $179.4 million of 2.25% convertibles
|
11/19/2020 | CVLM | Neurocrine to repurchase $83 million 2.25% convertible notes due 2024
|
11/19/2020 | CVLM | Neurocrine to repurchase $83 million of 2.25% convertible notes
|
9/14/2020 | CV | Market Commentary: Neurocrine Biosciences convertible notes gain; Ares Capital, Western Digital active
|
9/14/2020 | CV | Market Commentary: Morning Commentary: Ares Capital, Neurocrine Biosciences convertible notes active
|
9/9/2019 | CV | Market Commentary: Convertibles trade in line on swap; profit taking strikes a few names; Insulet drops with shares
|
9/9/2019 | CV | Market Commentary: Morning Commentary: Profit-taking strikes convertibles of Neurocrine, Blackstone, Ionis
|
7/30/2019 | CV | Market Commentary: RingCentral, NXP Semiconductors, Neurocrine Biosciences, Ligand active post-earnings
|
4/29/2019 | CV | Market Commentary: JPMorgan’s Voya-linked notes top par; Tesla remains in focus; Momo drops outright
|
4/29/2019 | CV | Market Commentary: Morning Commentary: JPMorgan’s Voya-linked notes top par; Neurocrine Biosciences active
|
4/11/2019 | CV | Market Commentary: PAR Technology convertible notes expand; Intercept down outright, up on hedge; biotechs active
|
1/8/2019 | CV | Market Commentary: Market eyes Colfax mandatory convertible offering; Illumina expands; Intel active
|
12/12/2018 | CV | Market Commentary: Medicines on tap; Neurocrine Biosciences expands; Splunk tops par; Tilray yield crosses 11%
|
12/12/2018 | CV | Market Commentary: Morning Commentary: Neurocrine Biosciences convertibles eyed on clinical trial failure
|
7/12/2017 | CV | Market Commentary: Morning Commentary: Liquidity limited amid little news to move markets; Tesla firms with stock
|
5/2/2017 | CV | Neurocrine greenshoe increases 2.25% convertibles to $517.5 million
|
5/1/2017 | CV | Market Commentary: Blackstone Mortgage in market; recent deals in play; BroadSoft hit post-earnings
|
5/1/2017 | CV | Market Commentary: Morning Commentary: Synchronoss active; Neurocrine holds in; Blackstone Mortgage in market
|
4/27/2017 | CV | Market Commentary: New convertibles from Flexion, Neurocrine jump over par post-pricing; Synchronoss suffers
|
4/27/2017 | CV | Market Commentary: Morning Commentary: New deals from Flexion, Neurocrine jump over par post-pricing
|
4/26/2017 | CV | New Issue: Neurocrine prices $450 million 2.25% seven-year convertible notes, up 42.5%
|
4/26/2017 | CV | Market Commentary: Twitter tops estimates, convertibles flat; Anthem firms on earnings; new deals on tap
|
4/26/2017 | CV | Market Commentary: Morning Commentary: Twitter beats estimates but little changed; Flexion, Neurocrine deals in focus
|
4/25/2017 | CV | Market Commentary: Flexion, Neurocrine add deals to calendar; Tesla, InterDigital little moved ahead of earnings
|
4/25/2017 | CV | Neurocrine offers $450 million seven-year convertible notes to yield 2.5%-3%, up 37.5%-42.5%
|
5/16/2006 | CV | Market Commentary: American Axle surges on possible loophole; DOV Pharmaceuticals falls, Sepracor gains on drug's rejection
|
8/12/2005 | BTCV | New Issue: Morgan Stanley prices $25 million 7.25% Perqs exchangeable for Neurocrine Biosciences
|